Brainstorm Cell Therapeutics Inc. (OTCPK: BCLI)
Health Care · Biotechnology · US
$0.98
-1.01% today · +52.6% 1Y
Brainstorm Cell Therapeutics Inc. (OTCPK: BCLI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.81M and employs 20 people.
Over the last twelve months the share price has gained 52.6%, trading between 0.46 and 1.69.
Tweenvest scores Brainstorm Cell Therapeutics Inc. across four factors: quality 6/100. Its strongest factor is quality.
BCLI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.81M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.95
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- $1.69
- 52-week low
- $0.46
- Avg volume (3M)
- —
- Shares outstanding
- 11.03M
- Employees
- 20
- Next earnings
- —
About Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
- ISIN
- US10501E3009
- Founded
- 2000
- Listed since
- Oct 7, 2003
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.